Samer Al Hadidi, Assistant Professor at UAMS Myeloma Center, shared a post on X:
“ASH24 The American Society of Hematology (ASH)
Oral Myeloma: Majestec-4/EMN30
Schema:
Patients got 3-4 drugs with 1-2 transplants and needed to have at least partial response
Maintenance study:
Dosing intensity per 3 cohorts Tec can be stopped after 1 year if in CR and at 2 years regardless, details.”
More posts featuring Samer Al Hadidi.
